Pharma Mar investor relations material

Pharma Mar, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company is also involved in the production of cytostatic products from plants; research into new molecules and marine organisms; provision of services for diagnosing cancer; and creation of molecules that inhibit the function of genes involved in human diseases. In addition, it offers RNA interference (RNAi) technology platform to design pharmaceuticals that act as synthetic RNAs targeting specific sequences by impairing the expression or activity of a protein to prevent the onset or progression of an illness or disease.